FIELD: medicine.
SUBSTANCE: invention refers to medicine and can be used for regulation of neutrophil activation by using lithium chloride.
EFFECT: invention enables reducing the level of neutrophil activation by reducing the expression level of CD11b and CD66b molecules.
1 cl, 2 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR SUPPRESSING EXCESSIVE NEUTROPHIL ACTIVATION IN AN EX VIVO MODEL | 2022 |
|
RU2794568C1 |
| METHOD FOR REDUCING INFLAMMATORY HYPERACTIVATION OF NEUTROPHILS | 2020 |
|
RU2758536C1 |
| REGULATOR OF NEUTROPHIL ACTIVATION | 2018 |
|
RU2742417C1 |
| METHODS OF DEPRESSING INFLAMMATION MEDIATOR RELEASE AND PEPTIDES APPLIED FOR THIS PURPOSE | 2007 |
|
RU2423376C2 |
| METHODS OF REGULATING INFLAMMATION MEDIATORS AND PEPTIDES USED IN THEM | 2007 |
|
RU2429004C2 |
| USE OF PEPTIDE FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2013 |
|
RU2672341C2 |
| CELLULAR SYSTEM FOR TARGETED DELIVERY OF A PHARMACEUTICALLY ACTIVE SUBSTANCE OR LABEL | 2016 |
|
RU2771323C2 |
| APPLICATION OF HEPARIN-BINDING ANTAGONISTS IN INHIBITING BRADYKININ RELEASING | 2000 |
|
RU2251433C2 |
| DIAGNOSTICS METHOD USING HNL | 2015 |
|
RU2758608C2 |
| CHIMERIC POLYPEPTIDE SELECTIVELY REACTING WITH RELATED CHEMOKINE RECEPTOR, PHARMACEUTICAL COMPOSITION AND APPLICATION OF CHIMERIC POLYPEPTIDE (VERSIONS) | 2005 |
|
RU2430113C2 |
